Corticosteroid Therapy in Equine Joint Disease: Intra-articular vs Systemic Use

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Intra-articular corticosteroid injection offers targeted, rapid anti-inflammatory effects for localized synovitis and osteoarthritis, achieving high clinical success rates (e.g., 87.8% with triamcinolone alone at three weeks) with minimal systemic exposure, though risks of iatrogenic septic arthritis and steroid arthropathy necessitate strict aseptic technique and judicious use.
• Systemic corticosteroid administration is reserved for polyarticular disease or when intra-articular access is limited, providing broader distribution but carrying predictable hypothalamic-pituitary-adrenal (HPA) axis suppression and increased laminitis risk, with a less robust evidence base for primary equine joint disease.
• Diagnostic assessment, including regional anesthesia, synovial fluid analysis (mandatory if sepsis is suspected, with specific cell counts and differentials guiding decisions), and radiography, is critical before corticosteroid selection to differentiate inflammatory from mechanical lameness and rule out contraindications like active infection or joint instability.
• Steroid arthropathy, characterized by accelerated cartilage and subchondral bone destruction, is an inherent risk of corticosteroid action, particularly with repeated or high-dose injections, and is best monitored clinically through serial lameness examinations, as radiographic changes lag behind clinical deterioration.
• Residual systemic endocrine effects, including prolonged cortisol suppression, have been documented even after intra-articular corticosteroid administration, impacting the horse's response to subsequent inflammatory challenges and necessitating careful record-keeping for regulatory and clinical management purposes.
• Reinjection intervals for intra-articular corticosteroids should be dictated by clinical recurrence of lameness and objective reassessment, rather than a fixed schedule, with more than two to three injections per joint annually warranting investigation for alternative diagnoses or therapeutic strategies.

Corticosteroids remain a central tool in managing equine joint disease, yet their use demands a clear understanding of the differences between intra-articular and systemic delivery. This article compares these two routes for the practicing veterinarian, addressing indications, mechanisms, risks, and monitoring strategies. It answers the clinical question of when one route should be preferred over the other, and how to mitigate the complications associated with each.

The comparison rests on the pharmacology of glucocorticoid action, the physiology of the diarthrodial joint, and the pathology of osteoarthritis and synovitis. Intra-articular injection delivers a high local concentration with minimal systemic exposure, while systemic administration distributes drug to multiple joints but at lower relative concentrations and with broader endocrine and metabolic effects. The evidence base for these approaches differs in maturity, with intra-articular therapy supported by decades of clinical use and a growing body of controlled trials, while systemic therapy for primary joint disease is less well characterized.

This reference is written for qualified veterinary practitioners who already understand joint anatomy, lameness evaluation, and basic corticosteroid pharmacology. It does not provide owner instructions or individualised dosing recommendations. Where specific doses appear in the literature, they are cited to their source and current formularies must be consulted before clinical application.

At a Glance

Physiology of the Equine Diarthrodial Joint

The equine joint consists of articular cartilage, synovial membrane, synovial fluid, and subchondral bone. Cartilage is avascular and relies on diffusion from synovial fluid for nutrition. Chondrocytes maintain the extracellular matrix, balancing synthesis and degradation of proteoglycans and collagen. Synovial fluid provides lubrication and shock absorption through hyaluronan and lubricin.

Inflammation disrupts this balance. Synovitis releases cytokines and matrix metalloproteinases that degrade cartilage and stimulate subchondral bone remodelling. The response of subchondral bone to osteochondral fragmentation includes increased vascularity and mineralising surface, changes that occur independently of corticosteroid treatment in experimental models. This finding from an equine carpal fragmentation study indicates that the structural damage of joint disease proceeds through pathways that corticosteroids may not fully address.

Pharmacology of Corticosteroids in Joint Disease

Corticosteroids bind cytoplasmic glucocorticoid receptors and modulate gene transcription. They suppress phospholipase A2 activity, reduce prostaglandin and leukotriene synthesis, and inhibit cytokine production from synovial macrophages and chondrocytes. The result is reduced synovial inflammation, decreased effusion, and improved lameness.

The two agents most commonly used intra-articularly in horses are triamcinolone acetonide and betamethasone. Both are relatively insoluble, providing a depot effect within the joint. Triamcinolone acetonide has been studied more extensively in controlled trials. A randomised multicentre trial of 80 lame horses compared triamcinolone acetonide alone with triamcinolone combined with hyaluronate, finding a clinical success rate of 87.8% for the corticosteroid alone at three weeks, compared with 64.1% for the combination. This result from a randomised open-label multicentre clinical trial challenges the assumption that adding hyaluronate improves short-term efficacy, although the study design was open-label and the mechanism for the difference remains unexplained.

Systemic corticosteroids for joint disease are used less frequently. Oral prednisolone or parenteral dexamethasone may be considered for polyarticular inflammation, but the evidence base in horses is thin. Extrapolation from other species is unreliable because equine glucocorticoid receptor sensitivity and metabolism differ. The MSD Veterinary Manual provides general pharmacology guidance, but specific equine joint indications require careful clinical judgment.

Intra-articular Corticosteroid Therapy

Intra-articular injection is indicated for noninfectious synovitis and osteoarthritis affecting one or a few joints. The goal is rapid reduction of inflammation with minimal systemic effect. Clinical response is typically assessed by lameness score and joint effusion at two to three weeks.

The risks are well documented. Septic arthritis is the most feared complication, and strict aseptic technique is mandatory. Steroid arthropathy, the accelerated cartilage destruction associated with repeated or high-dose injection, results from suppression of chondrocyte metabolism and matrix repair. This concern was articulated in a review of corticosteroid and hyaluronic acid treatments that noted the effect is inherent to the drug action instead of a technical failure. Rest following injection is important, as loading a joint with suppressed cartilage repair capacity may worsen damage.

Residual effects of intra-articular corticosteroids extend beyond the joint. A crossover study using an acute synovitis model found that both betamethasone and triamcinolone acetonide caused significant and prolonged cortisol suppression, and that a residual treatment effect persisted after subsequent lipopolysaccharide challenge. These findings from a study of residual effects of intra-articular corticosteroids indicate that even local injection has systemic endocrine consequences that may affect the horse's response to later inflammatory challenges.

Systemic Corticosteroid Therapy

Systemic corticosteroids are rarely the first choice for equine joint disease. Their use is reserved for situations where multiple joints are affected, where intra-articular injection is impractical or contraindicated, or where concurrent systemic inflammation is present. The advantages are uniform distribution to all synovial structures and avoidance of repeated joint penetration.

The disadvantages are substantial. Systemic glucocorticoids suppress the hypothalamic-pituitary-adrenal axis, increase the risk of laminitis, and may exacerbate latent infections. The relationship between systemic corticosteroid use and laminitis in horses is well recognized clinically, though the precise dose-response relationship is not firmly established. Monitoring should include serial lameness examinations, digital pulse assessment, and consideration of cortisol measurement in prolonged courses.

The evidence for systemic corticosteroids in equine joint disease is largely extrapolated from anti-inflammatory use in other conditions. No large controlled trials compare systemic corticosteroids with intra-articular therapy for osteoarthritis. This gap in the literature means the practitioner must weigh theoretical benefits against documented risks, and current formulary references should guide agent selection and dosing.

Comparative Decision Framework

The choice between intra-articular and systemic therapy depends on the number of affected joints, the chronicity of disease, the presence of sepsis, and the intended use of the horse. For a single joint with acute synovitis, intra-articular triamcinolone is well supported by trial evidence. For multiple joints or for a horse that cannot tolerate repeated joint injections, systemic therapy may be considered despite the weaker evidence base.

Septic arthritis is a contraindication to corticosteroid use until infection is controlled. In a series of 39 cases treated with repeated joint lavage, a single dose of short-acting corticosteroid was administered intra-articularly only after white blood cell count dropped below 15 G/l and bacterial culture was negative. This protocol from a clinical series of septic arthritis cases illustrates the principle that corticosteroids can be used after infection resolution, but never during active sepsis.

Diagnostic Assessment Before Corticosteroid Selection

The decision to use intra-articular or systemic corticosteroid therapy begins with a structured lameness examination. Localize the source of lameness with regional anesthesia before any corticosteroid is administered. Intra-articular analgesia of the suspect joint should be performed with an agent other than corticosteroid, and the response interpreted in light of concurrent perineural blocks. Synovial fluid analysis is mandatory before injection when sepsis is a possibility. Fluid that is turbid, hemorrhagic, or has a nucleated cell count above 10,000 cells per microlitre with a neutrophil fraction above 90 percent warrants culture and withholding of corticosteroid until infection is excluded. Radiography defines the degree of osteoarthritic change, identifies fractures, and reveals subchondral bone lysis that may alter the risk-benefit calculation. Advanced imaging with MRI or CT is indicated when radiographs are unremarkable but lameness persists after intra-articular analgesia, particularly in the proximal suspensory region, distal tarsal joints, or stifle.

The diagnosis must distinguish inflammatory joint disease from mechanical dysfunction. Corticosteroids suppress inflammation but do not address instability, meniscal tears, or collateral ligament injury. Injection of a lax joint can accelerate deterioration because pain relief permits increased loading of an already unstable articulation. This principle was recognized in early experimental work on intra-articular corticosteroid use, which concluded that injection may be beneficial when lesions are confined to soft tissues of the joint but is contraindicated when joint laxity is present Owen's investigation of intra-articular corticosteroid therapy in the horse. The same reasoning applies to systemic therapy, which provides less targeted analgesia but carries the same risk of masking mechanical failure.

Route Selection: Intra-articular Versus Systemic

Intra-articular injection delivers a high drug concentration to the target synovial structure with minimal systemic exposure. It is the preferred route for monoarticular or oligoarticular disease where a single joint or a small number of joints are responsible for lameness. Systemic administration is reserved for polyarticular inflammatory conditions, for joints that are difficult to inject reliably, or when the clinician wishes to avoid the risks of joint penetration. Systemic corticosteroids are also used in the management of septic arthritis after infection is controlled, where a single short-acting dose may limit secondary cartilage damage. One case series of septic arthritis treated with repeated joint lavage reported administration of a single dose of short-acting corticosteroid intra-articularly once the white blood cell count dropped below 15 G per liter and culture was negative Meijer and colleagues' clinical experience treating septic arthritis with repeated joint lavage. This practice remains controversial and should be applied only when synovial fluid parameters confirm resolution of infection.

The comparative decision framework below summarizes the clinical reasoning.

Drug Selection and Dosing Considerations

Triamcinolone acetonide is the most commonly used intra-articular corticosteroid in equine practice. It has a shorter duration of action than methylprednisolone acetate and is associated with a lower risk of steroid arthropathy. Betamethasone is an alternative with a similar profile. Methylprednisolone acetate is reserved for soft tissue structures such as the navicular bursa or when a longer duration of effect is desired, but its crystalline suspension carries a higher risk of post-injection flare and cartilage damage. A randomised multicentre trial comparing intra-articular triamcinolone alone with triamcinolone combined with hyaluronate found that triamcinolone alone produced a higher clinical success rate at three weeks, defined as a reduction of at least two lameness grades, with success rates of 87.8 percent and 64.1 percent respectively de Grauw and colleagues' randomised trial of triamcinolone with and without hyaluronate. This finding challenges the routine addition of hyaluronate and supports the use of triamcinolone as a single agent in most cases.

Dose selection depends on joint volume and disease severity. Current formulary references should be consulted for specific doses, as published ranges vary and label indications differ between regions. The clinician must also consider the horse's age. The same multicentre trial identified age over 13 years as a negative prognostic factor for response to intra-articular triamcinolone, suggesting that older horses may require adjunctive therapy or a different treatment plan de Grauw and colleagues' randomised trial of triamcinolone with and without hyaluronate.

Monitoring Parameters and Complication Surveillance

Monitoring after corticosteroid administration serves three purposes: confirming therapeutic response, detecting complications, and guiding reinjection intervals. Lameness should be reassessed at two to three weeks after intra-articular injection. A horse that has not improved by that point requires re-evaluation of the diagnosis instead of immediate reinjection. Synovial effusion should be scored at each examination, as persistent effusion despite lameness improvement may indicate ongoing synovitis.

Systemic effects of intra-articular corticosteroids are measurable. A crossover study using an acute synovitis model demonstrated that both betamethasone and triamcinolone acetonide produced significant and prolonged cortisol suppression after intra-articular injection Partridge and colleagues' study of residual effects of intra-articular betamethasone and triamcinolone. This suppression has implications for the timing of subsequent injections, for concurrent illness, and for horses competing under regulations that restrict corticosteroid use. The same study found residual treatment effects on inflammatory parameters after lipopolysaccharide challenge, indicating that the anti-inflammatory action persists beyond the period of visible lameness improvement.

Complications to monitor include post-injection flare, which typically presents within 24 to 48 hours with acute lameness and effusion. A mild flare may be managed with cold therapy and rest. A severe flare requires synovial fluid analysis to exclude sepsis. Steroid arthropathy remains a concern with repeated or high-dose injection. Experimental work in an equine carpal osteochondral fragment model found that triamcinolone treatment did not significantly alter subchondral bone remodelling parameters, but the study also demonstrated that fragmentation itself induced significant changes in the opposing bone Kawcak and colleagues' study of osteochondral fragmentation and triamcinolone treatment. This suggests that the underlying disease process, instead of the corticosteroid alone, drives much of the observed bone pathology.

Documentation and Reinjection Strategy

Every corticosteroid administration must be documented in the medical record with the drug, dose, joint, route, batch number, and the date. This record supports regulatory compliance, facilitates monitoring of cumulative exposure, and provides a basis for reinjection decisions. Reinjection intervals should be based on clinical response, not a fixed schedule. A horse that returns to soundness for six months after a single injection does not require another injection until lameness recurs. A horse that responds for only three weeks requires reassessment of the diagnosis and consideration of alternative therapies.

The cumulative number of injections per joint per year should be tracked. Published guidance and clinical experience suggest that more than two or three injections per joint per year warrants a search for an alternative explanation for persistent lameness. Systemic corticosteroid use should be documented with the same rigour, including the indication, dose, and duration of treatment. Horses receiving systemic corticosteroids should be monitored for the development of laminitis, gastric ulceration, and immunosuppression, particularly when treatment extends beyond a single dose.

Regulatory and Stewardship Considerations

Corticosteroid use in horses is subject to regulatory oversight that varies by jurisdiction and by the horse's intended use. Horses competing under rules that restrict medication require withdrawal periods that are specific to the drug, route, and dose. The clinician must consult current competition rules and national regulatory guidance before treating a horse that may compete. The United States Food and Drug Administration provides information on approved animal drugs, labeling, and extralabel use that is relevant to prescribing decisions FDA Center for Veterinary Medicine animal drug information. International movement of horses for competition or breeding may also be affected by medication records, and the World Organization for Animal Health publishes standards relevant to animal health and trade WOAH terrestrial animal health code.

Judicious use of corticosteroids is part of broader antimicrobial and anti-inflammatory stewardship. Corticosteroids should not be used as a substitute for accurate diagnosis, and their use should not delay the recognition of septic arthritis. The American Veterinary Medical Association publishes practice resources that support clinical decision-making and responsible medication use AVMA practice resources. The clinician should also consider whether non-steroidal anti-inflammatory drugs, physical therapy, or surgical intervention offer a better risk-benefit profile for the individual patient.

Recognized Complications and Early Detection

Intra-articular corticosteroid injection carries two principal failure modes: septic arthritis and steroid arthropathy. Septic arthritis follows inoculation of bacteria at injection time or through subsequent hematogenous seeding of a traumatised joint. Early detection depends on serial synovial fluid analysis. Total nucleated cell count rising above 30 x 10^9/L, neutrophil fraction above 90%, and protein above 40 g/L support infection, though counts may be lower early or after prior corticosteroid exposure. Cytology showing intracellular bacteria is definitive but absent in a substantial proportion of culture-positive joints. Synovial fluid glucose less than 2.8 mmol/L when blood glucose is normal adds diagnostic weight. Repeat sampling within 12 to 24 hours when suspicion persists is appropriate, a single negative culture does not exclude sepsis.

Steroid arthropathy is the accelerated cartilage and subchondral bone destruction attributed to suppression of chondrocyte metabolism and matrix maintenance. The 1981 review by Nizolek and White identified this effect as inherent to the drug's action instead of a technical error. Early detection is clinical: worsening lameness, increasing effusion, or new radiographic lucency in a treated joint within weeks to months of injection. Radiographic change lags clinical deterioration, so serial lameness examination remains the most sensitive monitoring tool. Advanced imaging such as MRI or CT may reveal subchondral bone injury before radiographic change appears, but these modalities are not justified for routine surveillance.

Corticosteroid-induced suppression of the hypothalamic-pituitary-adrenal axis occurs after intra-articular administration. In an acute synovitis model, both betamethasone and triamcinolone acetonide produced significant and prolonged cortisol suppression, with residual treatment effects still measurable after lipopolysaccharide challenge. Detection requires serum cortisol measurement, which is rarely performed in clinical practice. The practical consequence is that a horse treated intra-articularly may have blunted endogenous cortisol for weeks, which matters if the horse subsequently develops systemic illness or requires anesthesia. Clinicians should record the date, drug, and dose of every intra-articular injection in the medical record so that this information is available to other practitioners.

Common Errors and Corrective Actions

The most frequent error is injecting a joint without adequate diagnostic confirmation. Lameness localization by regional anesthesia, radiography, and synovial fluid analysis should precede corticosteroid injection. Injecting a joint with unrecognised sepsis converts a manageable infection into a corticosteroid-suppressed infection with a worse prognosis. A second error is repeated injection of the same joint at short intervals without objective reassessment. Reinjection is only justified when the prior response was documented, the lameness has returned to baseline, and the joint has been re-evaluated for new pathology.

A third error is failure to rest the joint after injection. Owen's 1980 work concluded that intra-articular corticosteroids may be beneficial when lesions are confined to soft tissues, but rest following therapy is important. Returning an athlete to full work immediately after injection risks mechanical overload of a joint whose protective pain response has been abolished. A fourth error is treating advanced osteoarthritis with corticosteroids alone when the primary problem is mechanical. Fragmentation studies show that osteochondral fragmentation induces significant remodelling in opposing subchondral bone, and corticosteroid treatment does not reverse that process. The clinician should distinguish inflammatory pain, which responds to corticosteroids, from mechanical pain, which does not.

Limitations of Current Evidence

The evidence base for intra-articular corticosteroid use is narrower than clinical practice suggests. One randomised multicentre trial compared triamcinolone acetonide alone with triamcinolone plus hyaluronate in 80 lame horses and found a higher success rate with triamcinolone alone at three weeks. This result contradicts the widespread belief that combination therapy is superior, but the trial was open-label and the three-week endpoint does not address long-term joint health. The same study noted that age over 13 years was associated with a reduced response, which is clinically plausible but not mechanistically explained.

Evidence on systemic corticosteroid use for equine joint disease is even more limited. Most published work addresses intra-articular therapy, and systemic corticosteroids are used largely on the basis of extrapolation from other species and from anti-inflammatory indications. Expert opinion differs on whether systemic corticosteroids have any role in chronic osteoarthritis, with some clinicians reserving them for acute inflammatory flares and others avoiding them entirely. The risk of steroid arthropathy is better documented for intra-articular use, but the systemic route does not eliminate the concern because drug concentrates in synovial fluid after oral or parenteral administration.

Escalation and Referral Criteria

Referral for specialist evaluation is warranted when lameness persists after two appropriately performed intra-articular injections, when synovial fluid findings are equivocal for sepsis, when radiographic changes are progressive despite treatment, or when the affected joint is a high-motion joint such as the stifle or fetlock with substantial effusion. Laboratory involvement is indicated for synovial fluid culture, cytology, and total protein measurement in any joint that fails to respond as expected. Regulatory reporting applies when an adverse drug event occurs with an approved product, the FDA Center for Veterinary Medicine maintains adverse event reporting pathways for animal drugs. International movement of treated horses may also require documentation of treatment history, and practitioners should consult current standards where trade or competition rules apply.

Frequently Asked Questions

How Should I Counsel an Owner About the Risks of Repeated Intra-articular Corticosteroid Injections?

Explain that intra-articular corticosteroids reliably reduce lameness in many cases, but the effect is not purely protective. The historical concern about steroid arthropathy stems from suppression of chondrocyte metabolism and impaired cartilage maintenance, as described in the review of corticosteroid and hyaluronic acid treatments in equine degenerative joint disease. Frame the discussion around risk mitigation: use the lowest effective dose, restrict high-impact exercise for an appropriate period after injection, and reassess lameness before each reinjection. Owners should understand that repeated injections do not replace ongoing joint management, and that any worsening of effusion or lameness after initial improvement warrants immediate re-evaluation instead of another injection.

What Should I Do When a Horse Presents with Acute Severe Lameness After a Recent Intra-articular Injection?

Treat this as septic arthritis until proven otherwise. The distinction between post-injection flare and infection is not always obvious, and delay in diagnosis worsens outcome. Joint lavage, synovial fluid sampling for cytology and culture, and systemic antimicrobial therapy should be initiated promptly. The case series on repeated joint lavage for septic arthritis demonstrates that aggressive lavage combined with appropriate antibiotics achieves good joint recovery rates in adults, and that a single intra-articular corticosteroid dose can be used once infection is controlled and white blood cell counts have fallen. Do not administer additional corticosteroids while infection is suspected. Refer early if you lack the facilities for repeated lavage or intensive monitoring.

How Do I Manage a Horse That Requires Systemic Corticosteroids for Another Condition While Also Having Active Joint Disease?

Prioritize the condition that poses the greater immediate threat. Systemic corticosteroids will suppress joint inflammation to some degree, but the effect is less predictable and less localized than intra-articular therapy. If the systemic course is short, defer intra-articular injection until systemic therapy is complete to avoid additive immunosuppression and to allow accurate lameness assessment. If the systemic course is prolonged, monitor the target joint closely for worsening effusion or lameness, and consider whether the systemic steroid dose can be reduced or the joint disease managed with non-steroidal anti-inflammatory drugs or physical therapy in the interim. Document the rationale clearly, as the interaction between systemic and intra-articular corticosteroids is not well characterized in the literature.

What Records Should I Keep for Intra-articular Corticosteroid Administration?

Record the joint injected, the specific product and dose, the batch number, the date, and the pre-injection lameness grade. Note the reason for choosing that particular joint and product, and document any concurrent medications. This information supports reinjection interval decisions and is essential if a complication such as septic arthritis or a suspected adverse drug reaction occurs. Regulatory expectations for drug records vary by jurisdiction, and the FDA Center for Veterinary Medicine provides guidance on approved drug labeling and adverse event reporting in the United States. In other regions, consult the relevant national authority. Accurate records also help you identify patterns, such as a joint that is deteriorating despite repeated injections, which should prompt reconsideration of the treatment plan.

How Should I Adapt My Approach When Point-of-Care Ultrasound or Advanced Imaging Is Unavailable?

Rely on a rigorous physical examination. Localize the lameness with flexion tests and perineural or intra-articular analgesia before injecting. Palpate for effusion, thickening, and heat, and compare the affected joint with the contralateral limb. If you cannot confirm the source of lameness with confidence, do not inject. Radiography remains widely available and should be used to rule out fractures, advanced osteoarthritis, or osteochondral fragmentation before corticosteroid injection. The study of osteochondral fragmentation and triamcinolone treatment shows that fragmentation induces significant subchondral bone changes, and injecting a joint with unrecognised fragmentation may mask lameness while bone pathology progresses. When imaging is limited, err toward conservative management and referral if the horse does not improve.

How Do I Explain the Difference Between Triamcinolone and Betamethasone to a Client Who Asks Why One Was Chosen?

Keep the explanation practical. Triamcinolone acetonide is the most commonly used intra-articular corticosteroid in equine practice and has demonstrated efficacy in clinical trials, with one multicentre trial reporting an 87.8% success rate for triamcinolone alone at three weeks. Betamethasone is also used and has a role, but comparative data on residual anti-inflammatory effects are limited to experimental models. Explain that product choice depends on the joint, the severity of disease, the practitioner's experience, and cost. Avoid implying that one drug is universally superior. Emphasize that the injection technique, the rest period, and the overall rehabilitation plan matter as much as the drug selected, and that the client's compliance with the aftercare protocol is critical to the outcome.

Related Clinical & Scientific Guides

• Veterinary Formulary Essentials: Navigating Drug References
• Drug Interactions with Antiepileptic Drugs in Veterinary Patients: Managing Polypharmacy
• Drug Interactions with Corticosteroids in Veterinary Patients: A Comprehensive Review

References and Further Reading

• Intra-articular treatment with triamcinolone compared with triamcinolone with hyaluronate: A randomised open-label multicentre clinical trial in 80 lame horses.. 2016.
• Corticosteroid and hyaluronic acid treatments in equine degenerative joint disease. A review.. 1981.
• Residual effects of intra-articular betamethasone and triamcinolone acetonide in an equine acute synovitis model.. 2023.
• Effects of osteochondral fragmentation and intra-articular triamcinolone acetonide treatment on subchondral bone in the equine carpus.. 1998.
• Intra-articular corticosteroid therapy in the horse.. 1980.
• Clinical experiences of treating septic arthritis in the equine by repeated joint lavage: a series of 39 cases.. 2000.
• FDA Center for Veterinary Medicine: Animal Drug Information. FDA CVM.
• AVMA Antimicrobial Use and Stewardship. American Veterinary Medical Association.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.

Related Articles

• Corticosteroid Therapy in Feline Inflammatory Bowel Disease: Dosing and Monitoring
• Antimicrobial Stewardship in Equine Respiratory Disease: Evidence-Based Use
• Corticosteroid Therapy in Feline Diseases: Special Considerations
• Corticosteroid Therapy in Canine Atopic Dermatitis: Dosing and Monitoring
• Corticosteroid Therapy in Canine Inflammatory Diseases: Balancing Efficacy and Safety

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.